Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Nanomedicines

Vertex to give Moderna $75 million to develop gene-editing therapies for cystic fibrosis

by Megha Satyanarayana
September 26, 2020 | A version of this story appeared in Volume 98, Issue 37

 

Vertex Pharmaceuticals will pay Moderna $75 million in an agreement to develop lipid nanoparticles and messenger RNA (mRNA) for the delivery of gene-editing cystic fibrosis (CF) therapies. The deal is the second between the two companies; the first involves developing a system to deliver mRNA encoding the CF protein directly to lung cells lacking functional versions of the protein. Both approaches that Vertex and Moderna are pursuing could help treat the 10% of people with CF who don’t respond to Vertex’s current CF drugs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.